> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly’s Tirzepatide Meets Trial Weight Loss Endpoints
- URL: https://www.fdaweb.com/lillys-tirzepatide-meets-trial-weight-loss-endpoints/
- Published: 2022-04-28T12:00:00.000Z
- Updated: 2026-09-14T17:42:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151697

Lilly says its tirzepatide achieved superior weight loss compared to placebo in the 72-week Phase 3 SURMOUNT-1 study. A company [statement](http://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or?ref=fdaweb.com) says the drug met both co-primary endpoints of superior mean percent change in body weight from baseline and a greater percentage of participants achieving body weight reductions of at least 5% compared to placebo. It says the study also achieved all secondary endpoints at 72 weeks.

Participants taking tirzepatide lost up to 52 pounds in the study and 63% of participants taking the 15 mg dose achieved at least 20% bodyweight reduction as a key secondary endpoint, Lilly says.

Tirzepatide is described as “a once-weekly glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single novel molecule.”